Alzheimer's disease (AD) is the most common cause of dementia. AD treatments currently approved are commonly regarded as purely symptomatic. Therefore, development of eŠective disease modifying treatments is eagerly required. Pathological hallmarks of AD brain include amyloid-b (Ab) accumulation, neuroˆbrillary tangle (NFT), synaptic loss, and neurodegeneration. Understanding of AD pathogenesis provides deep insight into the therapeutic approach for AD. In this review, we introduce our current translational researches for new therapeutic strategies against AD. We recently revealed that a key molecule for actin assembly, Wiscott-Aldrich syndrome protein family verprolin-homologous protein (WAVE), is accumulated into NFT in an Ab pathology-dependent manner. Because synaptic function is maintained by precise regulation of actin assembly, abnormal accumulation of WAVE induced by Ab pathology may expand the NFT pathology to synaptic dysfunction. These results imply that lowering of brain Ab at the early stage of AD pathogenesis is a promising therapeutic approach. As the approach for the elimination of brain Ab, we have studied microglial Ab phagocytosis and proposed its therapeutic application for AD treatment. We demonstrated that anti-Ab antibody and galantamine promote microglial Ab phagocytosis by binding to Fc receptors and nicotinic acetylcholine receptors on microglia, respectively. On the other hand, we demonstrated that the transplantation with microglia eŠec-tively eliminate brain Ab and microglia-like Ab phagocytic cells were successfully prepared from bone marrow derived cells by the stimulation with macrophage colony-stimulating factor. Thus, we have studied cell therapeutic strategy aim at its clinical application for AD treatment by the activation of endogenous microglia and transplantation of exogenous microglia-like Ab phagocytic cells.
A, Human brain tissues were immunostained with antibodies against hyperphosphorylated tau, phosphorylated CRMP2, and WAVE. No immunoreactivities of hyperphosphorylated tau and phosphorylated CRMP2 were detected in non-dementia (control) brain. WAVE immunoreactivity was slightly detected in neuronal perikarya of control brain. In AD brain, WAVE was accumulated with hyperphosphorylated tau and phosphorylated CRMP2 in NFTs and abnormal neurites. Scale bar＝20 mm for all panels in A. Phospho-Tau: phosphorylated tau, Phospho-CRMP2: phosphorylated CRMP2. B, Brains of Tg2576 mice, JNPL3 mice, and 3xTg-AD mice were immunostained with antibodies against Ab, hyperphosphorylated tau, phosphorylated CRMP2, and WAVE. In Tg2576 mice, extracellular Ab depositions were detected. In JNPL3 mice, accumulations of hyperphosphorylated tau and phosphorylated CRMP2 were detected in a part of neurons. In 3xTg-AD mice, Ab accumulations, and intraneuronal accumulations of hyperphosphorylated tau, phosphorylated CRMP2, and WAVE were detected. Scale bar＝50 mm for all panels in B. C, Schematic illustration of a possible pathway in Ab-dependent tangle maturation and synaptic deˆcit: Ab pathology may in‰uence on the accumulations of tau and/or CRMP2 by activation of several kinases for tau and CRMP2. In neurons, the accumulation of hyperphosphorylated tau induces CRMP2 accumulation. Ab pathology may also induce CRMP2 hyperphosphorylation before or after CRMP2 accumulation in the abnormal neurons. The accumulation of hyperphosphorylated CRMP2 may induce abnormal WAVE accumulation and result in synaptic dysfunction through the disturbance of actin assembly. A, Human AD brain tissues were immunostained with antibodies against ionized calcium-binding adapter molecule 1 (microglial marker, green) and glialˆbrillary acidic protein (Astrocyte marker, red), and counter-stained with a dye for Ab plaques (FSB, blue). Microglia and astrocytes were accumulated on senile plaques. Scale bar＝50 mm for all panels in A. B, Primary-cultured rat microglia was treated with Ab peptides. After the treatment, microglia was immunostained with antibody against Ab (green) and counter-stained with dyes for actinˆlament (phalloidin-rhodamine, red) and nucleus (Hoechst 33342, blue). After the treatment of Ab, microglia transformed its morphology rod shape to amoeboid shape and phagocytosed Ab. Image analysis revealed that the amount of Ab phagocytosed by rat microglia was gradually increased in a time-dependent manner. Scale bar＝ 10 mm for all panels in B. 
